公司资料
Adlai Nortye Ltd. 股价、新闻与催化剂
- 股票代码:
- ANL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
15.76 USD (-1.50%)
收盘价
最后更新: 2026年10月1日
746M USD
市值
股价为何变动
截至 2026年10月1日，ANL 下跌 1.50%，收于 $15.76。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.
所在地与行业分类
Annovis is headquartered in the United States and listed on NASDAQ. It sits in neuroscience biotechnology.
商业模式特征
The company depends on clinical proof, translational confidence, and the ability to keep a narrow pipeline funded. Investors usually watch early data and whether the biology can support a meaningful CNS thesis.
生物医药行业定位
Annovis occupies a high-risk neurodegeneration niche within biotech. The stock is highly dependent on whether the company can show a real disease-modifying effect.
未来催化剂
- Adlai Nortye’s catalysts are its oncology pipeline and any clinical update that clarifies whether the company can still build a meaningful development story. The stock remains early and data-dependent.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。